Replies to post #134011 on Biotech Values

[DewDiligence]

…if there is much shorter life expectancy, it would take less time to do survival trials and therefore drugs could run through phase III studies that much faster.

However, the decreased lifespan would not necessarily lead to a higher proportion of successful trials relative to all trials being conducted, so it isn’t clear that the result would be more approved drugs.